Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently?
Perrine Janiaud, Lars G. Hemkens, John P. A. Ioannidis
Canadian Journal of Cardiology (2021) Vol. 37, Iss. 9, pp. 1353-1364
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

The impact of the COVID-19 pandemic on scientific research in the life sciences
Massimo Riccaboni, Luca Verginer
PLoS ONE (2022) Vol. 17, Iss. 2, pp. e0263001-e0263001
Open Access | Times Cited: 160
The Integration of Clinical Trials With the Practice of Medicine
Derek C. Angus, Alison J. Huang, Roger Lewis, et al.
JAMA (2024) Vol. 332, Iss. 2, pp. 153-153
Closed Access | Times Cited: 23
Interventions for mental health, cognition, and psychological wellbeing in long COVID: a systematic review of registered trials
Lisa D. Hawke, Anh T. P. Nguyen, Chantal F. Ski, et al.
Psychological Medicine (2022) Vol. 52, Iss. 13, pp. 2426-2440
Open Access | Times Cited: 41
What SARS-CoV-2 does to our brains
Tom Aschman, Ronja Mothes, Frank L. Heppner, et al.
Immunity (2022) Vol. 55, Iss. 7, pp. 1159-1172
Open Access | Times Cited: 40
COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment
Luis Ortega‐Paz, Azita H. Talasaz, Parham Sadeghipour, et al.
Seminars in Thrombosis and Hemostasis (2022) Vol. 49, Iss. 08, pp. 816-832
Open Access | Times Cited: 29
Randomized trials on non-pharmaceutical interventions for COVID-19: a scoping review
Julian Hirt, Perrine Janiaud, Lars G. Hemkens
BMJ evidence-based medicine (2022) Vol. 27, Iss. 6, pp. 334-344
Open Access | Times Cited: 28
Aggressive measures, rising inequalities, and mass formation during the COVID-19 crisis: An overview and proposed way forward
Michaéla C. Schippers, John P. A. Ioannidis, Ari R. Joffe
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 28
Challenges and solutions in clinical research during the COVID‐19 pandemic: A narrative review
Mahin Nomali, Neda Mehrdad, Mohammad Heidari, et al.
Health Science Reports (2023) Vol. 6, Iss. 8
Open Access | Times Cited: 18
Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials
Sa’ed H. Zyoud
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Five aspects of research waste in biomedicine: A scoping review
Louise Olsbro Rosengaard, Mikkel Zola Andersen, Jacob Rosenberg, et al.
Journal of Evidence-Based Medicine (2024) Vol. 17, Iss. 2, pp. 351-359
Open Access | Times Cited: 4
The COVID-19 impact: Insights into the pharmaceutical sector through 10-K reports
Shan Wang, Fan Yang, Xinyue Fang, et al.
International Journal of Engineering Business Management (2025) Vol. 17
Open Access
From Emergence to Endemicity: A Comprehensive Review of COVID-19
Roopa Naik, Sreekant Avula, Sujith K Palleti, et al.
Cureus (2023)
Open Access | Times Cited: 11
Drug Repurposing During The COVID-19 Pandemic: Lessons For Expediting Drug Development And Access
Wesley Greenblatt, Charu Gupta, Jennifer L. Kao
Health Affairs (2023) Vol. 42, Iss. 3, pp. 424-432
Open Access | Times Cited: 10
Characteristics and Research Waste Among Randomized Clinical Trials in Gastric Cancer
Jun Lü, Binbin Xu, Lili Shen, et al.
JAMA Network Open (2021) Vol. 4, Iss. 9, pp. e2124760-e2124760
Open Access | Times Cited: 16
What did COVID‐19 really teach us about science, evidence and society?
Andrea Saltelli, Joachim P. Sturmberg, Daniel Sarewitz, et al.
Journal of Evaluation in Clinical Practice (2023) Vol. 29, Iss. 8, pp. 1237-1239
Open Access | Times Cited: 6
Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial
Alejandro Llanos–Cuentas, Alvaro Schwalb, Juan Luis Quintana, et al.
BMC Research Notes (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 5
Use of pragmatic randomized trials in multiple sclerosis: A systematic overview
Julian Hirt, Perrine Janiaud, Pascal Düblin, et al.
Multiple Sclerosis Journal (2024) Vol. 30, Iss. 4-5, pp. 463-478
Open Access | Times Cited: 1
Exploring Study Design Foibles in Randomized Controlled Trials on Convalescent Plasma in Hospitalized COVID-19 Patients
Massimo Franchini, Carlo Mengoli, Arturo Casadevall, et al.
Life (2024) Vol. 14, Iss. 7, pp. 792-792
Open Access | Times Cited: 1
Ethical and informative trials: How the COVID-19 experience can help to improve clinical trial design
Emma Law, Isabel M. Smith
Research Ethics (2024) Vol. 20, Iss. 4, pp. 764-779
Open Access | Times Cited: 1
What are the clinical and research lessons learned from immunomodulators and other therapies during the COVID-19 pandemic?
Daniel A. Sweeney, Pedro Póvoa
Current Opinion in Critical Care (2024) Vol. 30, Iss. 5, pp. 420-426
Closed Access | Times Cited: 1
Factors that influence recruitment to COVID-19 vaccine trials: a qualitative evidence synthesis
Linda Biesty, Sarah Sheehan, Pauline Meskell, et al.
Trials (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials
Denise Battaglini, Chiara Robba, Paolo Pelosi, et al.
Expert Opinion on Emerging Drugs (2022) Vol. 27, Iss. 2, pp. 187-209
Closed Access | Times Cited: 7
SARS-CoV-2 and the Vaccination Hype
Piero Sangaletti, Jane Doe, Antonietta Gatti, et al.
International Journal of Vaccine Theory Practice and Research (2022) Vol. 2, Iss. 1, pp. 173-207
Open Access | Times Cited: 7
The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges
John W. Eikelboom, Sumathy Rangarajan, Sanjit S. Jolly, et al.
CJC Open (2022) Vol. 4, Iss. 6, pp. 568-576
Open Access | Times Cited: 6
Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?
Denis Horgan, Tanja Španić, Kathi Apostolidis, et al.
Healthcare (2022) Vol. 10, Iss. 8, pp. 1594-1594
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top